Background While transcatheter aortic valve implantation (TAVI) is established for treating highoperative risk surgical aortic valve replacement candidates, until recently the smallest transcatheter heart valve (THV) measured 23 mm, posing greater risk for annular rupture and THV failure in patients with aortic stenosis (AS) with small aortic annuli (≤20 mm). Objectives In the setting of a multicentre registry, we report on the safety, efficacy and early clinical outcomes of the SAPIEN XT 20 mm balloon-expanding THV. Results Among TAVI 55 recipients (n=30 for native AS, n=25 for a valve-in-valve procedure (V-in-V)), median age and Society of Thoracic Surgeons score were 85 (81 to 87) years and 7.8 (4.7 to 12.4)%, respectively. Mean and minimum annular diameters were 19±1 and 17±2 mm, respectively, in native patients with AS, and 17±1 mm (internal diameter) in V-in-V recipients. Successful device implantation rate was 96%, with no procedural-related death. Overall in-hospital-30-day death, stroke and major bleeding rates were 5%, 2% and 9%, respectively. In native AS TAVI recipients, mean transaortic gradient decreased from 54±20 to 12±5 mm Hg ( p<0.001), and from 45±17 to 24±8 mm Hg ( p<0.001) in V-in-V recipients. Severe prosthesis-patient mismatch (PPM) rates were 10% and 48% in native AS and V-in-V TAVI recipients, respectively ( p=0.03). Post-TAVI, the rate of moderate aortic regurgitation was 7% and 0% in native AS and V-in-V TAVI recipients, respectively. Conclusions TAVI with the 20 mm SAPIEN XT THV appears safe and technically feasible, with acceptable short-term clinical outcomes and low rates of severe PPM in those with native AS.
INTRODUCTION
The combination of a small aortic annulus (≤20 mm) with severe aortic stenosis (AS) requiring treatment poses a unique therapeutic challenge. Aortic root enlargement coupled with surgical aortic valve replacement (SAVR), is considered 'gold standard' for optimising long-term clinical and haemodynamic outcomes in such individuals. 1 2 However, annular enlargement procedures are rarely performed due to limited expertise as well as questionable efficacy in the elderly who frequently harbour calcified aortic roots, 3 invariably resulting in greater rates of severe prosthesis-patient mismatch (PPM) in these SAVR recipients, adversely impacting patient survival. 4 5 Transcatheter aortic valve implantation (TAVI) is an established treatment for patients with severe, symptomatic AS at high or prohibitive surgical risk for SAVR. 6 TAVI has also emerged as an effective treatment option for patients with failing surgical aortic bioprostheses, yet those with small diameter (≤20 mm) failing surgical valves that have undergone transcatheter valve-in-valve (V-in-V) procedures have demonstrated greater risk of PPM and mortality from implanting transcatheter heart valves (THVs) within originally relatively undersized surgical valves. 7 Despite TAVI's emergence and success in the elderly high-operative risk population, until recently the smallest available THV was 23 mm in size. THV oversizing carries the inherent risk of annular rupture ( particularly with balloonexpandable THVs) and THV dysfunction due to suboptimal deployment. The 20 mm SAPIEN XT balloon-expanding valves (Edwards LifeSciences, Irvine, California, USA) is currently the smallest commercially available THV, offering a unique alternative for treating high-operative risk, severe native patients with AS with small aortic annuli. However, current experience with this valve has been limited to a few single case reports. [8] [9] [10] The objective of the present registry was to report on the initial safety, efficacy and early clinical outcomes of the SAPIEN XT 20 mm THV.
METHODS
This multicenter registry was designed to collect data of implanted SAPIEN XT 20 mm THVs across sites in Europe and Canada. The main characteristics of the 20 mm SAPIEN XT THV are shown in figure 1 . The 20 mm SAPIEN XT valve is implanted (transfemoral approach) with the NovaFlex delivery system that is advanced through an expandable 16F sheath (Edwards LifeSciences). Data involving TAVI within a native aortic valve or a V-in-V procedure using the SAPIEN THV were accepted. A total of 23 centres submitted data until mid-December 2015 using a dedicated case report form. Any missing data or inconsistencies were directly resolved with the THV implanters. All patients provided informed consent to undergo TAVI within each local treating institution.
The Society of Thoracic Surgeons (STS) score (http://riskcalc. sts.org/de.aspx) and/or the Logistic EuroSCORE (http://www. euroscore.org/calcold.html) were used to predict operative mortality in the event of conventional SAVR for each patient undergoing TAVI or V-in-V. Internal diameters of previously implanted surgical valves were provided by each site and were derived from their respective labels and manufacturing charts.
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Aortic annular measurements were obtained from 3D CT exams and valve sizing was based on manufacturer recommendations and the Valve in Valve app (for V-in-V procedures). Clinical end points were assessed according to the Valve Academic Research Consortium (VARC)-2 criteria. 12 Early post-TAVI echocardiographic data were derived either immediately following TAVI or within the same hospital admission, and these data were used to calculate and define the severity of PPM. 13 Severe PPM was defined as the aortic valve effective orifice area (EOA) divided by body surface area (BSA) of <0.65 cm 2 /m 2 .
Statistical analysis
Results are expressed as means±SD or median (IQR) for continuous variable and percentages for categorical variables. Differences between patients with native versus V-in-V were compared with the use of the Student's t-test for continuous variables, the Wilcoxon rank-sum test as appropriate for comparisons between two groups and the χ 2 test or Fisher's exact test for categorical variables as appropriate. Paired t-tests were used to assess differences in pre-TAVI and post-TAVI haemodynamic results. Comparisons of the change in haemodynamic results were performed using analysis of covariance, adjusting for the preprocedural value. A p value <0.05 was considered statistically significant. Statistical analyses were performed using SAS V.9.4 software (SAS Institute, Cary, North Carolina, USA). Table 1 describes baseline characteristics of the overall patient cohort, divided into those who underwent native versus V-in-V TAVI (n=30 and 25, respectively).
RESULTS
The overall median age was 85 (81 to 87) years, with a strong female preponderance (89%). The median overall STS and EuroSCORE were 7.8 (4.7 to 12.4)% and 20.4 (12.1 to 33.0)%, respectively, with the V-in-V cohort harbouring a significantly greater operative risk profile than the population undergoing TAVI for native AS. Table 2 describes annular measurements for both native AS and V-in-V TAVI recipients.
In native AS TAVI recipients, by CT, the mean annular diameter was 19±1 mm, with an annular area of 305±30 mm 2 . In V-in-V recipients, the listed original prosthetic valve sizes were 19, 21 and 23 mm, comprising 28%, 60% and 12% of V-in-V recipients, respectively, with a mean internal valve diameter of 17±1 mm. The mechanism of prosthetic valve failure necessitating a V-in-V intervention was predominantly AS, predominantly aortic regurgitation (AR), or mixed AS/AR in 52%, 16% and 32% of V-in-V recipients. Table 3 describes periprocedural and in-hospital/30-day clinical results.
The transfemoral approach was the predominant means of procedural access (93% overall). Overall, successful device implantation occurred in all patients undergoing V-in-V procedures, and in 93% of patients undergoing TAVI within native AS. Balloon post-dilation was undertaken in four patients. There were no cases of annulus rupture, coronary obstruction, valve embolisation/need for a second valve or periprocedural deaths. The in-hospital/30-day mortality rate was 5%, with an overall VARC-2-defined major bleeding rate of 9%, a major vascular complication rate of 9% and a stroke rate of 2%. Table 4 summarises the pre-TAVI and post-TAVI haemodynamic results. In patients undergoing TAVI for native AS, the baseline mean transaortic gradient decreased significantly from 54±20 to 12 ±5 mm Hg ( p<0.001 from baseline). In V-in-V recipients, mean transaortic gradient decreased significantly from 45±17 to 24 ±8 mm Hg( p<0.001frombaseline). Thechange inmeantransaortic gradient was significantly greater in those patients undergoing TAVI for native AS compared with those undergoing a V-in-V procedure ( p<0.001). In patients undergoing TAVI for native AS, the baseline aortic valve area increased significantly from 0.50 (0.40 to 0.60) cm 2 to 1.20 (1.11 to 1.50) cm 2 ( p<0.001). Similarly, in V-in-V recipients, the prosthetic valve area also increased significantly from 0.60 (0.50 to 0.70) cm 2 to 1.00 (0.90 to 1.10) cm 2 ( p=0.002). The change in EOAwas significantly greater in those patients undergoing TAVI for native AS compared with those undergoing a V-in-V procedure (+0.80 (0.60 to 1.00) vs +0.30 (0.10 to 0.50) cm 2 , p<0.001). Severe PPM was present in 10% of native AS TAVI recipients compared with 48% of V-in-V recipients ( p=0.03). Figure 2 demonstrates pre-TAVI and post-TAVI rates of AR. In those patients with native AS undergoing TAVI, moderate AR post-TAVI was evident in 2 patients (7%), with either mild AR or no/trace AR evident in the remaining 28 patients (93%). In the V-in-V recipients, there were eight patients (32%) who demonstrated moderate-severe AR at baseline. Post V-in-V, no patient demonstrated at least moderate AR, with mild AR found in 16% and trace-no AR in the remaining 84% of V-in-V recipients.
DISCUSSION
The evolution of TAVI has provided an alternative treatment paradigm for elderly high-operative risk patients with severe AS and small aortic annuli. However, until recently the smallest commercially available THVs measured 23 mm in diameter, posing potential risks for annular rupture and THV failure due to relative valve oversizing. In the present multicentre registry of patients who underwent TAVI with currently the smallest commercially available THV (measuring 20 mm), we outline for the first time the feasibility, safety and acceptable haemodynamic performance of this device in both patients with native AS and those undergoing a V-in-V intervention. There were no periprocedural deaths, annular ruptures, valve migration or coronary obstruction, and in-hospital/30-day clinical event rates (overall 5% death, 2% stroke, 9% major VARC-2-defined bleeding and vascular complication rates) were consistent with contemporary TAVI outcomes data. 14 15 Furthermore, the overall rate of moderate AR (<5%) was somewhat lower than that reported in contemporary real-world TAVI cohorts within both the V-in-V and native aortic valve TAVI recipients, 14 15 with a relatively low rate of severe PPM among native AS patients.
Aortic annulus rupture remains the most worrisome TAVI-related complication. This complication, although rare, is associated with a mortality rate as high as 50%. 16 The use of excessively oversized balloon-expandable valves has been identified as the most important predictor of annular rupture during TAVI. 16 Of note, the use of 23 mm balloon-expandable valves in (5) 3 ( Data are shown as n (%). *The VARC-2 criteria stipulate that successful device implantation incorporates a residual mean transaortic gradient <20 mm Hg. However, in patients with small aortic annuli, this correlates with greater transaortic gradients, especially in V-in-V recipients who inevitably harbour initially oversized previously surgically implanted prostheses. Therefore, for the sake of this niche small annulus cohort, device success incorporated acute technical success in the absence of vascular complications and greater than moderate aortic regurgitation, without a specific post-TAVI transaortic gradient criteria. †Transaortic gradient post-TAVI. AS, aortic stenosis; NA, not applicable; TAVI, transcatheter aortic valve implantation; V-in-V, valve-in-valve procedure.
the current population of patients with small aortic annuli would have been associated with some degree of excessive oversizing, leading to a potential increased risk of annular rupture/haematoma. The current series reporting no cases of mechanical complications following TAVI with a 20 mm balloon-expandable valve is therefore reassuring. Importantly, this was achieved with no cases of valve embolisation, malposition or severe residual AR, and a low rate of balloon post-dilation, suggesting that current sizing recommendations for the use of such valves seem appropriate. From a haemodynamic perspective, THVs have demonstrated superior profiles compared with surgical valves implanted in the aortic position. Clavel et al 17 retrospectively matched TAVI recipients (who received either the first-generation Cribier-Edwards or SAPIEN 23 or 26 mm THV) and SAVR recipients (who received both stented and stentless valves, n=50 per group) according to sex, aortic annulus diameter, left ventricular function, body surface area and body mass index. Trans-prosthetic gradients were significantly lower in TAVI (10 mm Hg) compared with SAVR recipients (14 mm Hg), with the differences in gradients driven almost entirely by those individuals harbouring annular diameters ≤20 mm. Kalavrouziotis et al 18 retrospectively examined the haemodynamic performance of the 23 mm SAPIEN THV in 35 TAVI recipients with small native aortic annuli (<20 mm). Interestingly, the haemodynamic performance of a relatively oversized THV was still nonetheless maintained, with a mean post-TAVI aortic gradient of 12 mm Hg, with a 6% severe PPM rate. However, 2D echocardiographic measures were used for valve sizing, and a larger aortic annulus measurement would likely have been obtained had 3D CT been used. Early results from the present registry using the 20 mm SAPIEN XT THV demonstrate equivalent results, with a mean post-TAVI trans-prosthetic gradient of 12 mm Hg and a 10% severe PPM rate in those patients undergoing TAVI within native aortic valves. By contrast, a post hoc analysis from the Placement of Aortic Transcatheter Valves demonstrated severe PPM rates of 20% and 37% in TAVI and SAVR recipients with small aortic annuli. 4 Given the known association between severe PPM and greater morbidity and mortality in both SAVR and TAVI recipients, 5 19 findings of the present analysis could bear clinical importance should these relatively low PPM rates be replicated in larger patient cohorts over longer follow-up periods.
To date, the Achilles heel of TAVI compared with SAVR is the greater incidence of residual AR, with rates of moderate-severe AR post-TAVI with balloon-expanding valves being of the order of 10-14% with earlier generation THV devices. While newer generation devices have been iterated to minimise the presence and severity of AR, moderate-severe post-TAVI AR remains an important predictor of mortality, being virtually absent post SAVR. 20 In the present analysis, within those patients undergoing TAVI within native aortic valves, residual moderate-severe AR post-TAVI was present in two patients (7%). While these observations are limited to a small-sized yet 'real-world' TAVI population, they are nevertheless reassuring. Valve oversizing can result in a greater propensity for PPM, although concomitantly lessening the severity of AR. In patients with small aortic annuli undergoing TAVI, post-TAVI AR and PPM tend to be inversely related (greater PPM rates with lesser AR), yet each of these entities are adversely prognostic. A sex-specific paradox following aortic valve interventions whereby women demonstrate significantly less morbidity and mortality post-TAVI, yet greater morbidity and mortality post SAVR was recently demonstrated. 21 This could relate to the superior haemodynamic profile of THVs (ie, less PPM with TAVI) with concomitantly less frequent moderatesevere AR post-TAVI in women who more frequently harbour smaller aortic annuli. Indeed, annulus size per se has been shown to be an independent factor associating with clinical and haemodynamic outcomes in favour of TAVI compared with SAVR. 4 This could suggest that certain degrees of PPM may be more tolerable than moderate-severe AR. Hence, the potential to optimally size and place THVs in small aortic annuli, thus minimising both PPM and post-TAVI AR, as well as avoiding annulus rupture could represent a key, yet niche feature of small-sized THVs.
The V-in-V subpopulation within the present analysis comprised of higher-risk patients than their native AS TAVI counterparts, akin to that previously described in a larger V-in-V cohort. 7 There was a 100% procedural success with the 20 mm SAPIEN THV, without periprocedural mortality, and in-hospital/30-day adverse clinical event rates did not differ from those undergoing TAVI within native aortic valves. Significant reductions in transprosthetic gradients were achieved, although less than the native AS population. Post-TAVI, there was a 48% incidence of severe PPM, suggesting the high prevalence of relatively undersized surgical valves that were originally implanted in these patients with small aortic annuli. No V-in-V recipient demonstrated moderatesevere AR however. Although these are short-term data within a limited sample size, they are nevertheless reassuring. Potential V-in-V candidates are inherently more complex than regular TAVI candidates, given that the mechanism(s) of original surgical valve failure could be manifold, with the possibility of significant degrees of PPM being present immediately following SAVR. In such patients, the placement of a small-sized THV is thus unlikely to alleviate the adverse haemodynamic conditions across the originally implanted prosthetic valve. Given that survival within a large global V-in-V cohort was lowest within the cohort of patients with small bioprostheses, 7 a smaller THV could represent a possible, effective therapeutic option in carefully selected potential V-in-V candidates.
There are a number of potential clinical implications for the evolution of smaller THVs. Patients with small aortic annuli presently comprise approximately 15% of current TAVI recipients, 4 and given the inevitable shift of TAVI towards lower surgical-risk candidates, this number is expected to rise. TAVI is also likely to ultimately gain significant traction in Asia, a population more likely to harbour smaller aortic annuli. Presently, the optimal treatment strategy of patients with AS with small aortic annuli is unknown. The availability of dedicated smallsized THVs should provide impetus for both manufacturers and investigators alike to explore the longer-term safety and efficacy of both TAVI and SAVR in this niche AS population.
Several limitations of the current analysis warrant consideration. These data pertain to balloon-expanding THVs only and should not be directly transferable to self-expanding THVs. To date, this is a relatively small-sized registry limited to Canada and Europe reporting a limited duration of clinical and haemodynamic follow-up. There was no central Core Laboratory adjudicating Doppler echocardiographic data, and uniform THV sizing criteria was applied to patients within this registry, as local implanters undertook imaging at their own discretion for procedural planning. As such, the results of the present registry, while novel, should be considered as hypothesis generating warranting confirmation in larger populations over longer time periods. This registry's expansion in terms of both patient numbers and duration of follow-up will shed further light on the longer-term clinical and haemodynamic outcomes of TAVI in patients with small aortic annuli.
In conclusion, TAVI with the 20 mm SAPIEN XT THV appears safe and technically feasible in patients with small aortic annuli, with acceptable short-term clinical outcomes and low rates of both AR and severe PPM in those with native AS. Longer-term follow-up in larger numbers of patients is required to confirm these initial findings, along with a formal evaluation of the optimal treatment approach for severe patients with AS with small aortic annuli. 
Key messages
What is already known on this subject? Performing transcatheter aortic valve implantation (TAVI) in patients with small aortic annuli (≤20 mm) with relatively oversized transcatheter heart valves (THVs; ≥23 mm) poses potential risk for annular rupture and THV dysfunction, yet until recently the smallest THV available measured 23 mm.
What might this study add? This is the first systematic report of the feasibility, safety and early clinical and haemodynamic performance of the 20 mm SAPIEN XT balloon-expanding THV, currently the smallest commercially available THV. We present data of TAVI recipients for both native aortic stenosis (AS) and those who underwent valve-in-valve (V-in-V) TAVI. TAVI with the 20 mm SAPIEN XT THV appears safe and technically feasible, with acceptable short-term clinical outcomes and very low rates of both aortic regurgitation (AR) and severe prosthesis-patient mismatch (PPM) in those with native AS.
How might this impact on clinical practice? Currently, patients with severe aortic AS and small aortic annuli pose a therapeutic challenge to achieve optimal haemodynamic and clinical outcomes. Conventional surgical aortic valve replacement, coupled with aortic annular enlargement, is performed only in selected patients. Given the emergence of TAVI, as well as the known haemodynamic superiority of THVs compared with surgical aortic valves, these data, if replicated in a larger prospective clinical trial, suggest that the optimal balance between low rates of PPM as well as AR is achievable when TAVI is undertaken with a small THV in those with small aortic annuli. Contributors RP planned the study, collected all data, wrote the manuscript. JB, RM, HB, HE, SR, AC, CD, LI, HCW, AC, MG, KEK, MP, RB-M, RE, CG, DM, FM, J-MS, PS, VV and MV contributed patient data and performed these procedures, provided critical manuscript review. AR contributed patient data, performed these procedures and provided critical manuscript review. MT provided critical manuscript review. PP helped planned the study and provided critical manuscript review. EP-B collected data, performed statistical analysis, drafted manuscript and provided critical review, drafted figures. JR-C contributed patient data, planned the study and provided critical manuscript review. Ethics approval The study protocol was performed in accordance with the institutional ethics committees.
Competing interests
Provenance and peer review Not commissioned; externally peer reviewed.
